Title: OPKO Health Inc (OPK) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ...
Date: 2025-05-01 07:17
URL: https://finance.yahoo.com/news/opko-health-inc-opk-q1-071721036.html?.tsrc=rss

Tip: Try a valid symbol or a specific company name for relevant results
More Americans are claiming Social Security early. Here's why.
Nvidia CEO Jensen Huang gets first salary boost in 10 years
Trump's tariffs are pulling in billions, but the revenue boom could be short-lived. Here's why.
S&P 500 wipes out Trump tariff losses, marks longest winning streak in 20 years as trade war cools
China says 'the door is open' to trade talks, while Canada's Carney is set to meet with Trump next week.
Investors cheered a solid jobs report and a thaw in US-China relations. The S&P 500 eyed its longest win streak in over 20 years.
Trump once again called on the Fed to lower rates. But the jobs report could reinforce Chair Powell's cautious stance.
Dow, S&P 500, Nasdaq jump amid jobs report beat, hopes for US-China talks
The US economy added 177,000 jobs in April as the labor market remained resilient in the wake of Trump's tariffs
The AI revolution is an advertising revolution
China says it’s evaluating US talks after weeks of stalemate (Bloomberg)
The April jobs report comes at a critical moment for markets. Here's what to expect.
'People are visiting less': Food chains warn tariffs are triggering a pullback in spending
Apple beats earnings on strong iPhone sales, authorizes $100 billion stock buyback
Watch our special report with insights, analysis, and key takeaways from Apple's high-stakes update.
Amazon beats on earnings but stock sinks as forecast spooks investors
Nasdaq surges as AI trade reignites amid Big Tech earnings; Dow, S&P 500 rise for 8th day
Even as Tesla's board denied kicking off a search to replace Musk, one analyst thinks it could help push him out of government.
Manufacturing activity in the US hit a five-month low in April, as Trump's tariffs left businesses in a 'state of near paralysis'
The Nasdaq surged over 2% as upbeat Microsoft and Meta results boosted optimism around Big Tech
Nasdaq leads way higher as stocks rally after Microsoft, Meta beats reassure Wall Street
Weekly jobless claims jumped to their highest level in two months, in the latest sign of a labor market slowdown
The month that Trump blinked on trade
Negative GDP is the latest data to offer 2 views on the US economy
The tech giant is set to report earnings Thursday with Trump's tariff whiplash in focus. Here's what to expect.
Here's how the courts could upend Trump's tariffs
Oil prices post biggest monthly drop since 2021 as trade war sparks recession, demand fears
Meta stock jumps after strong earnings, upbeat outlook shrugs off tariff worries
Microsoft stock soars after company beats on earnings, defying tariff fears
Stocks recover from sharp losses to cap volatile April fueled by tariff uncertainty
Trump decried 'Biden's Stock Market' after his 100th day in office was capped by another series of dour economic indicators
A pair of economic reports just delivered the Fed a 'stagflation warning shot'
Dow, S&P 500, Nasdaq fall after bleak GDP and jobs data, with Big Tech earnings on deck
Wall Street was setting up for a rough open after data showed the US economy contracted. Nasdaq futures lost nearly 2%.
The US economy contracted for the first time in three years start 2025, while prices increased more than forecast.
The US economy may have avoided a recession so far. Here's how that could change.
Corporate earnings tell 2 different consumer stories
The tech giant is set to report earnings on Wednesday under growing pressure to deliver on AI. Here's what to expect.
Trump: 'I have a Fed person who is not really doing a good job'
Trump's next tariff war will be with your favorite store
Why Wall Street is wary of the stock market rally
Dow extends longest win streak of 2025 as stocks climb amid latest tariff relief
From 'destacking' of tariffs to reimbursements for foreign parts, the US will offer relief to weary automakers.
Consumer confidence plunged for the fifth straight month, dropping to a level not seen since the early days of the pandemic
The White House took aim at Amazon over reports it would display tariff price impacts on products
S&P 500, Nasdaq slip amid rush of earnings, hopes for auto tariff relief
How Trump is answering (or dodging) questions on his historically bad 100-day stock market
Big Tech’s big week of tariff guidance
Trump has been president for 100 days, and it's clear he peaked on day one.
Widely criticized student loan servicer MOHELA faces investigation by multiple state attorneys general
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Diagnostics Segment Revenue: $102.8 million in Q1 2025, including $25.1 million from assets being sold to LabCorp, compared to $126.9 million in Q1 2024.
Diagnostics Segment Costs and Expenses: $126.8 million in Q1 2025, including $32.4 million related to assets being sold to LabCorp, compared to $161.3 million in Q1 2024.
Operating Loss (Diagnostics Segment): $23.9 million in Q1 2025, compared to $34.4 million in Q1 2024.
Pharmaceutical Segment Revenue: $47.1 million in Q1 2025, compared to $46.8 million in Q1 2024.
RAYALDEE Revenue: $6.3 million in Q1 2025, compared to $6.9 million in Q1 2024.
Net Loss: $67.6 million or $0.10 per share in Q1 2025, compared to $81.8 million or $0.12 per share in Q1 2024.
Cash Position: Approximately $450 million in cash, cash equivalents, and restricted cash at the end of Q1 2025.
Headcount Reduction: Reduced by 136 positions in Q1 2025, representing a 7% workforce reduction.
Annualized Cost Savings: Estimated at approximately $19 million from actions initiated in Q1 2025.
Total Revenue Guidance for 2025: Between $675 million and $685 million.
Costs and Expenses Guidance for 2025: Between $825 million and $875 million, excluding nonrecurring expenses.
Warning! GuruFocus has detected 6 Warning Signs with OPK.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
OPKO Health Inc (NASDAQ:OPK) announced the sale of BioReference's Health Oncology and related clinical testing business to LabCorp, unlocking additional value in their Diagnostics segment.
The company is advancing its dual-GLP-1/Glucagon agonist, OPK-88006, for the treatment of NASH, with promising preclinical results.
OPKO Health Inc (NASDAQ:OPK) entered into a collaborative agreement with Entera Bio to develop an oral tablet form of OPK-88006, potentially enhancing its market reach.
The company's Latin American business and EirGen Pharma continue to show revenue and profit growth.
The Board approved a $100 million increase to the common stock repurchase program, indicating confidence in the company's valuation and financial health.
The Diagnostics segment saw a revenue decrease to $102.8 million in Q1 2025 from $126.9 million in the same period of 2024, primarily due to previous transactions with LabCorp.
OPKO Health Inc (NASDAQ:OPK) reported a net loss of $67.6 million for the first quarter of 2025, although this was an improvement from the previous year's loss.
The company incurred $7.2 million in nonrecurring costs and expenses related to severance and facility closures.
Revenue from RAYALDEE decreased slightly due to the challenging environment created by the Inflation Reduction Act.
The company anticipates a nonrecurring other expense item related to a convertible debt exchange of approximately $90 million during the second quarter of 2025.
Q: What are some possible explanations for the negative dynamics for NGENLA? Is it more likely competition, access issues, or something commercial related to Pfizer? A: Adam Logal, CFO, explained that the growth rates of prescriptions for both NGENLA and GENOTROPIN continue, suggesting the issue might be related to the commercial environment. They expect this to be a first-quarter-only event, which is why the guidance was only slightly reduced.
Q: Could you comment on why Pfizer withdrew their EU application for the adult setting and what are the plans for expansion into additional settings? A: Adam Logal, CFO, noted that Pfizer is focusing on expanding the label for NGENLA, particularly in pediatric indications due to the larger market size compared to adults. The decision to withdraw the EU application for adults was likely strategic to focus efforts on pediatric indications.
Q: Could you provide a rough timeline for the development program of the GLP-1/Glucagon tablet candidate? A: Adam Logal, CFO, stated that they expect to file an IND by the end of this year or early next year, with trial commencement thereafter. Results from a Phase I trial could be available by the end of 2026, with expected once-weekly dosing.
Q: What are the next steps for the subcutaneous obesity and MASH program, and how do you anticipate differentiating the oral formulation? A: Elias Zerhouni, President, explained that both the subcutaneous and oral formulations are in the pre-IND phase. The focus is on safety and dose range in Phase I trials. The oral formulation is once a day, while the subcutaneous is once a week, with a focus on liver diseases affected by fatty liver disease.
Q: Can you provide an update on the Epstein-Barr virus (EBV) trial and any efficacy signals that might de-risk the asset? A: Elias Zerhouni, President, mentioned that the trial involves 200 healthy volunteers in different cohorts to test adjuvants. The focus is on tolerability and safety, with immunogenicity measured through biomarkers, providing an idea of potential efficacy.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Despite strength in OPKO Health's revenues from the transfer of intellectual property, the company reports an overall soft first-quarter 2025 performance.
Centene, Pediatrix Medical, Pfizer, StoneCo and Banco Santander have been highlighted in this Screen of The Week article.
The S&P 500 advanced 0.6% on Thursday, May 1, securing its eighth straight winning session as strong results from Microsoft and Meta helped boost tech stocks.
Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat estimates. Stock declines.
We recently published a list of 10 Jim Cramer Stocks to Watch Amid Trump Tariff Wars. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other stocks that Jim Cramer discussed. Jim Cramer in a latest program on CNBC talked about the latest signs of de-escalation […]
Buying a stock is easy, but buying the right stock without a good strategy is incredibly hard. Here are five top-performing stocks to buy now or put on a watchlist.
Recessions happen, but they can have severe negative consequences for your savings and finances. To minimize its impact on your life, take these steps to recession-proof your savings.
Imagine that you have $900,000 in a Roth IRA and collect another $2,200 per month in Social Security. Can you afford to retire at age 66? A good way to answer this question is to start with your budget. What do you expect to spend on essentials, like housing and fixed monthly expenses, and what […] The post I Have $900k in a Roth IRA and Would Receive $2,200 Monthly From Social Security. Can I Retire at 66? appeared first on SmartReads by SmartAsset.
Tip: Try a valid symbol or a specific company name for relevant results
Sign in to access your portfolio